세계의 경동맥 화학색전술(TACE) 시장 규모, 점유율, 성장 분석 : 시술 유형별, 제품 유형별, 적응증별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Transarterial Chemoembolization Market Size, Share, and Growth Analysis, By Procedure Type, By Product Type, By Indication, By End-User, By Region - Industry Forecast 2025-2032
상품코드:1681605
리서치사:SkyQuest
발행일:2025년 03월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
경동맥 화학색전술(TACE) 시장 규모는 2023년 102억 달러로 평가되었습니다. 또한, 2024년 106억 6,000만 달러에서 2032년에는 151억 6,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 4.5%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
세계 경동맥 화학색전술(TACE) 시장은 간염 감염, 알코올 사용, 비알코올성 지방간 질환 등의 요인으로 인한 간암 유병률 증가와 간종양 치료에 대한 저침습적 접근으로 인해 소비자 선호도가 변화하고 있습니다. 의료기술의 혁신으로 TACE 시술이 더욱 정교해지고, 정확도가 향상되고, 비용이 절감됨에 따라 수요가 증가하고 있습니다. 간암의 증상과 조기 진단의 중요성에 대한 인식이 높아짐에 따라, 특히 중등도 이상의 간암 환자들은 조기에 치료를 받도록 유도하고 있습니다. 그러나 시장 역학은 지역마다 다르며, 의료 인프라, 위험 요인 발생률, 규제 프레임워크 등에 영향을 받습니다. 특히 중국을 비롯한 아시아태평양에서는 간암 발생률이 높기 때문에 큰 성장세를 보이고 있습니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 상황
사례 연구
기술 진보
경동맥 화학색전술(TACE) 시장 규모 : 시술 유형별&CAGR(2025-2032년)
시장 개요
기존 TACE
DEB-TACE
경동맥 화학색전술(TACE) 시장 규모 : 제품 유형별&CAGR(2025-2032년)
시장 개요
화학요법
방사선 치료제
약물 용출 입자
경동맥 화학색전술(TACE) 시장 규모 : 적응증별&CAGR(2025-2032년)
시장 개요
절제 불가능한 간세포암
조기 단계 간세포암
경동맥 화학색전술(TACE) 시장 규모 : 최종사용자별&CAGR(2025-2032년)
시장 개요
병원 및 진료소
암 연구센터
경동맥 화학색전술(TACE) 시장 규모 : 지역별&CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년대비 비교(2022-2024년)
주요 기업 개요
Meril Life Sciences(India)
MicroPort(China)
Terumo Corporation(Japan)
Ethicon(Johnson & Johnson)(United States)
Neusoft Medical Systems Co., Ltd.(China)
Merit Medical Systems, Inc.(United States)
Guerbet Group(France)
AngioDynamics, Inc.(United States)
Boston Scientific(United States)
Medtronic(Ireland)
Beckton Dickinson(United States)
Cook Group(United States)
HealthTronics(United States)
IceCure Medical(Israel)
Profound Medical(Canada)
Siemens Healthineers(Germany)
GE Healthcare(United States)
Philips Healthcare(Netherlands)
Sirtex Medical(Australia)
BTG plc(United Kingdom)
결론과 제안
LSH
영문 목차
영문목차
Transarterial Chemoembolization Market size was valued at USD 10.2 billion in 2023 and is poised to grow from USD 10.66 billion in 2024 to USD 15.16 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).
The global transarterial chemoembolization (TACE) market is experiencing a shift in consumer preferences due to its minimally invasive approach to treating hepatoma, in response to the rising prevalence of liver cancer driven by factors such as hepatitis infections, alcohol use, and non-alcoholic fatty liver disease. Innovations in medical technology have led to more sophisticated TACE procedures, enhancing accuracy and reducing costs, thereby boosting demand. Increased awareness regarding liver cancer symptoms and the importance of early diagnosis is prompting patients to seek treatment earlier, particularly for intermediate-grade cases. However, market dynamics vary by region, influenced by healthcare infrastructure, risk factor incidence, and regulatory frameworks, with significant growth observed in the Asia-Pacific region due to higher liver cancer rates, notably in China.
Top-down and bottom-up approaches were used to estimate and validate the size of the Transarterial Chemoembolization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Transarterial Chemoembolization Market is segmented by Procedure Type, Product Type, Indication, End-User and region. Based on Procedure Type, the market is segmented into Conventional TACE and DEB-TACE. Based on Product Type, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents and Drug-eluting Particles. Based on Indication, the market is segmented into Unresectable HCC and Early-Stage HCC. Based on End-User, the market is segmented into Hospitals and Clinics and Cancer Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Transarterial Chemoembolization Market
The Transarterial Chemoembolization (TACE) market is being propelled by the rising global prevalence of liver cancer, which necessitates effective treatment options. In addition, advancements in medical technology are enhancing the precision and effectiveness of these therapeutic procedures, influencing both healthcare providers and patients to opt for TACE. The appeal of minimally invasive techniques plays a significant role in the growth of this market, as they minimize discomfort and pain compared to conventional treatment approaches. As the demand for innovative and less intrusive cancer treatment continues to grow, TACE is emerging as a favored choice among patients and oncologists alike.
Restraints in the Transarterial Chemoembolization Market
The Transarterial Chemoembolization (TACE) market faces significant challenges stemming from the diverse nature of liver cancer patients and their varied responses to treatment. This complexity necessitates a tailored approach to TACE, hindering its widespread adoption. Additionally, stringent regulations surrounding the approval and reimbursement of medical procedures further constrain market growth. Variations in reimbursement policies and lengthy regulatory approval processes can impede the integration of TACE into standard healthcare practices, ultimately limiting its accessibility and use among patients. Consequently, these factors collectively act as significant restraints on the TACE market, affecting its overall development and implementation.
Market Trends of the Transarterial Chemoembolization Market
The Transarterial Chemoembolization (TACE) market is witnessing a significant trend towards personalized medicine, which emphasizes tailored treatment approaches for liver cancer patients. Healthcare providers are increasingly exploring customized TACE strategies based on individual patient characteristics, overall health status, and specific tumor types. This shift aligns with the broader movement toward precision medicine, aiming to optimize patient outcomes through bespoke therapies. Additionally, technological innovations are revolutionizing the TACE landscape, with ongoing research focused on enhancing the precision and efficacy of treatment. Advances in embolic agents, drug-eluting bead technologies, and imaging tools are enabling more targeted interventions, ensuring that the therapeutic impact on cancerous tissues is maximized while minimizing harm to surrounding healthy organs. This dual trend of personalization and technology integration is poised to drive growth in the TACE market.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement
Global Transarterial Chemoembolization Market Size by Procedure Type & CAGR (2025-2032)
Market Overview
Conventional TACE
DEB-TACE
Global Transarterial Chemoembolization Market Size by Product Type & CAGR (2025-2032)
Market Overview
Chemotherapeutic Agents
Radiotherapeutic Agents
Drug-eluting Particles
Global Transarterial Chemoembolization Market Size by Indication & CAGR (2025-2032)
Market Overview
Unresectable HCC
Early-Stage HCC
Global Transarterial Chemoembolization Market Size by End-User & CAGR (2025-2032)
Market Overview
Hospitals and Clinics
Cancer Research Centers
Global Transarterial Chemoembolization Market Size & CAGR (2025-2032)
North America (Procedure Type, Product Type, Indication, End-User)
US
Canada
Europe (Procedure Type, Product Type, Indication, End-User)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Procedure Type, Product Type, Indication, End-User)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Procedure Type, Product Type, Indication, End-User)
Brazil
Rest of Latin America
Middle East & Africa (Procedure Type, Product Type, Indication, End-User)
